This clinical trial will determine if a study medicine is safe and tolerable, and if it can help hair grow back in people 12 years of age or older with moderate alopecia areata.
This study is seeking participants who:
Learn more (English)
Learn more (Spanish)
This clinical trial is enrolling adults and adolescents 12 years of age or older who are generally healthy (or have stable medical conditions), have been diagnosed with alopecia areata, do not have hair loss caused by any other conditions, and have been experiencing hair loss for longer than 6 months but less than 10 years.
Participants will receive care from a team of dedicated medical professionals while contributing to research that could help people around the world.
Ritlecitinib is approved in many countries at a dose of 50 mg (milligram) taken by mouth once a day for the treatment of patients 12 years and older with severe alopecia areata. This study will look at both the 50 mg dose and a 100 mg dose.